Karolinska Development’s portfolio company SVF Vaccines initiates clinical phase 1 study of its universal Covid-19 vaccine
STOCKHOLM, Sweden, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, formerly Svenska Vaccinfabriken Produktion AB, has initiated a clinical phase 1 study of the company’s universal Covid-19 vaccine, SVF-002. The aim of the study is to evaluate the safety profile and immunogenicity of the vaccine candidate.
SVF Vaccines develops therapeutic proteins and DNA vaccines targeting, among others, Covid-19 and hepatitis B. Therapeutic vaccines have, in comparison to prophylactic vaccines, the potential to cure already infected patients. SVF-002 is, like several other vaccines against Covid-19, directed against the spike protein of SARS-CoV-2, the virus that causes Covid-19, but has also been designed to induce a T-cell response that is capable of eliminating cells in which the virus is present.
The phase 1 study is conducted by the OpenCorona consortium, which has a license to perform the study with SVF-002, in collaboration with the phase 1 unit at the Karolinska University Hospital. OpenCorona is a network of academic and commercial organizations that have received funding for the study from the European Union’s Horizon 2020 program. The aim of the study is to evaluate the safety profile and ability to create an immune response, immunogenicity, when administered to healthy subjects who have received three prior doses of an mRNA-based Covid-19 vaccine.
"Inducing a T-cell response is particularly important for eliminating infections in people whose antibody response to vaccination is poor. In preclinical studies, it has been shown that the SVF-002 vaccine can induce both a strong antibody response against SARS-CoV-2 and a broad T-cell response against beta-coronavirus," says Viktor Drvota, CEO of Karolinska Development.
Karolinska Development's ownership in SVF Vaccines amounts to 35 percent.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: email@example.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Innovative Producer, Filmmaker and Author Mick Ebeling to Join Duck Creek’s Formation ’23 as Keynote Speaker27.3.2023 14:30:00 CEST | Press release
Ebeling will discuss pushing the bar and making the inconceivable, the unbelievable and the impossible, not impossible Boston, March 27, 2023 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, welcomes Mick Ebeling as its Formation ’23 keynote speaker. Formation, Duck Creek’s annual user conference, attracts the world’s leading insurance industry and technology minds and takes place in Orlando, FL, May 8-10, 2023. Ebeling is the founder and CEO of Not Impossible, a critically acclaimed, award-winning social lab and production company that taps into the power of technology and story to change the world. Formation '23 will empower the P&C and general insurance community with the insights, technology, and inspiration to build better human experiences. As the industry comes together to collaborate and reimage the future of P&C technology, the conference’s theme, “building together,” is me
NGS Group AB: Kallelse till årsstämma i NGS Group AB (publ)27.3.2023 14:15:00 CEST | Pressemelding
Aktieägarna i NGS Group AB (publ), org. nr 556535-1128 ("Bolaget") kallas härmed till årsstämma torsdagen den 27 april 2023, kl. 15.00 i Bolagets lokaler på Kungsgatan 12 i Stockholm. Inregistrering till stämman påbörjas klockan 14:30. Rätt att delta på bolagsstämman Aktieägare som vill delta på bolagsstämman ska: dels vara införd i den av Euroclear Sweden AB förda aktieboken avseende förhållandena per avstämningsdagen onsdagen den 19 april 2023,dels anmäla sig för deltagande på bolagsstämman till Bolaget under adress NGS Group AB (publ), Thomas Plate, Kungsgatan 12, 111 35 Stockholm, per telefon 0768-949 239 eller via e-post till firstname.lastname@example.org. Anmälan ska vara Bolaget tillhanda senast fredagen den 21 april 2023. Vid anmälan ska uppges namn, person- eller organisationsnummer (eller motsvarande), e‑postadress eller telefonnummer dagtid, samt antal aktier och eventuella biträden. Förvaltarregistrerade aktier För att ha rätt att delta i stämman måste en aktieägare som låtit förvaltarr
Transactions in connection with share buyback programme27.3.2023 14:07:42 CEST | Press release
On 8 February 2023, Pandora announced a new share buyback programme, cf. Company announcement no. 769. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation). The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes. Under the programme Pandora will repurchase shares for an aggregate maximum amount of DKK 2.4 billion with an intention to go up to a total of DKK 5.0 billion during the next 12 months, depending on how the macroeconomic climate develops throughout the year. The programme commenced on 8 February 2023, cf. Company Announcement no. 769, and will conclude no later than 2 February 2024. The following transactions have been made under the programme: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated under the programme1,180,000760,396,825 20 Ma
Zoom announces the expansion of Zoom IQ, the smart companion that empowers collaboration and unlocks potential27.3.2023 14:01:10 CEST | Press release
Zoom uses OpenAI technologies to bolster a unique federated approach to AI based on flexibility SAN JOSE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Today at Enterprise Connect, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the expansion of Zoom IQ, a smart companion that empowers collaboration and unlocks people’s potential by summarizing chat threads, organizing ideas, drafting content for chats, emails, and whiteboard sessions, creating meeting agendas, and more. The company also announced it will use OpenAI to bolster its unique federated approach to AI based on flexibility. Zoom’s federated approach to AI leverages its own proprietary AI models, those from leading AI companies– such as OpenAI –and select customers’ own models. With this flexibility to incorporate multiple types of models, Zoom’s goal is to provide the most value for its customers' diverse needs. These models can also be customized to perform better for a customer, based on their vocabulary and requirement
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences27.3.2023 14:00:00 CEST | Press release
BOSTON and LONDON, March 27, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Genomic Medicines and Rare Disease Days Date: Monday, April 3, 2023 Location: New York, NY Fireside Chat: 9:35 AM ET Event: Jefferies & Venrock Boston Biotech Summit Date: Wednesday, April 12, 2023 Where applicable, the presentation slides and/or a link to the live webcast of the event, as well as an archived recording, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. About Centessa Pharmaceuticals Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medi